Kenya ’ s Population Growth Decreases as More Women Embrace Modern Family Planning
Pharmacists, like Christine Atieno​ from Mediway Healthcare and doctors say women and men in Kenya are more open to contraceptive use now. CREDIT: Wilson Odhiambo/IPS By Wilson OdhiamboNAIROBI, Aug 28 2023 (IPS) According to a family planning brief, more than 370 million women in middle and low-income countries were finally embracing modern contraception to help curb unintended pregnancies. This statistic suggests that one in every three women from middle and low-income countries use contraceptives today. Africa, which had the lowest number of family planning users in 2012, had registered a 66 percent increase, from 40...
Source: IPS Inter Press Service - Health - August 28, 2023 Category: International Medicine & Public Health Authors: Wilson Odhiambo Tags: Africa Development & Aid Education Featured Gender Global Headlines Health Humanitarian Emergencies Population Sustainable Development Goals TerraViva United Nations Women's Health IPS UN Bureau IPS UN Bureau Report Kenya Source Type: news

Bill & Melinda Gates Foundation, Children & #039;s Investment Fund Foundation, Pfizer and Becton, Dickinson & Company expand partnership for greater access to injectable contraceptive for women in low- and lower-middle-income countries
To help enable greater access to injectable contraceptives for millions of women in low- and lower-middle income countries, the Bill & Melinda Gates Foundation, Children's Investment Fund Foundation (CIFF), Pfizer and Becton, Dickinson & Company (BD) announced the expansion of their nearly decade-long collaboration. The expanded collaboration is expected to deliver more than 320 million doses of Pfizer's injectable contraceptive, Sayana® Press (medroxyprogesterone acetate)(1) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030. (Source: World Pharma News)
Source: World Pharma News - August 4, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

When Can Menstrual Suppression Start in Patients with a Disability?
Discussion Menstrual suppression using hormonal therapy is commonly used for a variety of reasons: Patient preference Contraception Heavy or painful menses Treatment of concomitant problems such as menstrual migraine, mood issues, nausea Specific patient populations Disabilities Oncology Transgender and gender nonbinary Methods of suppression include: Estrogen and progesterone Combined oral contraceptives (COC) – very good menstrual suppression and generally used as first line treatment for many patients Traditional dosing with active medication for 21-24 days and then 4-7 day placebo break. Extended cycles &...
Source: - February 14, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Prempro, Premphase (Conjugated Estrogens, Medroxyprogesterone Acetate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 7, 2021 Category: Drugs & Pharmacology Source Type: news

CDC: Self-Administered Subcutaneous DMPA Should Be Made Available
FRIDAY, May 21, 2021 -- Self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) should be made available as an additional approach for contraception, according to research published in the May 21 issue of the U.S. Centers for... (Source: - Pharma News)
Source: - Pharma News - May 21, 2021 Category: Pharmaceuticals Source Type: news

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
This report describes updated recommendations for the use of self-administered injectable contraception. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 20, 2021 Category: American Health Tags: Birth Control Contraception MMWR Morbidity & Mortality Weekly Report Source Type: news

Depo-SubQ Provera (Medroxyprogesterone Acetate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 3, 2020 Category: Drugs & Pharmacology Source Type: news

SABCS: Breast Cancer Rates Opposite for Estrogen, Estrogen & #43; Progestin
FRIDAY, Dec. 13, 2019 -- For postmenopausal women, conjugated equine estrogen (CEE) alone is associated with a long-term decrease in breast cancer incidence, while CEE plus medroxyprogesterone acetate (MPA) is associated with increased incidence,... (Source: - Pharma News)
Source: - Pharma News - December 13, 2019 Category: Pharmaceuticals Source Type: news

Contraceptive drug shows promise for preventing and regressing cervical cancer
(Elsevier) A new study in The American Journal of Pathology, published by Elsevier, reports that medroxyprogesterone acetate (MPA), the active ingredient in the common contraceptive injection Depo-Provera, was effective in preventing the development of cervical cancer in mice with precancerous lesions. The drug also decreased existing precancerous lesions. If proven effective clinically, MPA may be a boon to women who do not have access to human papillomavirus (HPV) vaccines. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 12, 2019 Category: Cancer & Oncology Source Type: news

Make Hormonal Contraceptives Available OTC, ACOG Says Make Hormonal Contraceptives Available OTC, ACOG Says
Updated guidance from the ACOG advocates making vaginal rings, the contraceptive patch, and depot medroxyprogesterone acetate available for purchase over the counter along with oral contraceptives.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 25, 2019 Category: Endocrinology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Drug Supply issues: Sayana Press (medroxyprogesterone acetate) and Hormone replacement therapy (HRT)
Information from the Department of Health and Social Care (DHSC) regarding the following supply issues... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - August 28, 2019 Category: Drugs & Pharmacology Source Type: news